Previous Close | 40.750 |
Open | 40.350 |
Bid | 41.500 x 0 |
Ask | 41.550 x 0 |
Day's Range | 39.800 - 41.700 |
52 Week Range | 35.000 - 77.400 |
Volume | |
Avg. Volume | 17,839,821 |
Market Cap | 176.314B |
Beta (5Y Monthly) | 1.23 |
PE Ratio (TTM) | 41.92 |
EPS (TTM) | 0.990 |
Earnings Date | Aug 23, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 81.61 |
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics ("Amicus") (Nasdaq: FOLD) on receiving European Commission's approval for Pombiliti™ (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD).
Q4 2022 Amicus Therapeutics Inc Earnings Call
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a license agreement with GSK plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms.